As the U.S. market navigates a landscape of tariff exemptions and fluctuating tech stock performance, investors are keenly observing opportunities that may arise from these developments. For those interested in smaller or newer companies, penny stocks — despite their somewhat outdated moniker — remain a relevant investment area. When supported by solid financial health, these stocks can offer a blend of value and growth potential that might not be as prominent in larger firms.
Name
Share Price
Market Cap
Financial Health Rating
Safe Bulkers (NYSE:SB)
$3.48
$364.86M
★★★★☆☆
Tuya (NYSE:TUYA)
$2.02
$1.2B
★★★★★★
CI&T (NYSE:CINT)
$4.87
$651.45M
★★★★★☆
Smith Micro Software (NasdaqCM:SMSI)
$0.796
$14.15M
★★★★☆☆
Global Self Storage (NasdaqCM:SELF)
$4.93
$55.56M
★★★★★☆
Flexible Solutions International (NYSEAM:FSI)
$3.83
$48.44M
★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)
$2.33
$70.67M
★★★★★★
BAB (OTCPK:BABB)
$0.7755
$5.63M
★★★★★☆
QuantaSing Group (NasdaqGM:QSG)
$3.08
$226.43M
★★★★★★
Lifetime Brands (NasdaqGS:LCUT)
$3.99
$88.43M
★★★★★☆
Click here to see the full list of 795 stocks from our US Penny Stocks screener.
We’ll examine a selection from our screener results.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for advanced wound care and surgical and sports medicine markets in the United States, with a market cap of $540.29 million.
Operations: The company generates revenue primarily from its Regenerative Medicine segment, amounting to $482.04 million.
Market Cap: $540.29M
Organogenesis Holdings Inc., with a market cap of US$540.29 million, recently joined the S&P Biotechnology Select Industry Index, highlighting its presence in the sector. Despite being unprofitable and experiencing high share price volatility, it reported a net income of US$7.67 million for Q4 2024, a turnaround from the previous year’s loss. The company is debt-free and has strong short-term assets exceeding liabilities by over US$200 million, providing financial stability. However, significant insider selling raises concerns about internal confidence despite forecasts of substantial earnings growth and trading at good value compared to peers.
NasdaqCM:ORGO Revenue & Expenses Breakdown as at Apr 2025
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Alight, Inc. is a technology-enabled services company operating globally with a market cap of approximately $2.64 billion.
Operations: The company’s revenue is primarily derived from its Employer Solutions segment, which generated $2.33 billion.
Market Cap: $2.64B
Alight, Inc., with a market cap of approximately US$2.64 billion, remains unprofitable but has shown progress by reducing its net loss to US$157 million in 2024 from US$345 million the previous year. The company has improved its debt-to-equity ratio significantly over five years and maintains a positive cash runway for over three years due to growing free cash flow. Alight’s short-term assets exceed short-term liabilities; however, long-term liabilities remain uncovered. Recent board changes and enhancements in their Alight Worklife® platform aim to strengthen their service offerings and operational efficiency amidst ongoing volatility and undervaluation concerns.
NYSE:ALIT Debt to Equity History and Analysis as at Apr 2025
Simply Wall St Financial Health Rating: ★★★★★★
Overview: VTEX, along with its subsidiaries, offers a software-as-a-service digital commerce platform for enterprise brands and retailers, with a market cap of approximately $897.84 million.
Operations: The company’s revenue is primarily generated from its Internet Software & Services segment, totaling $226.71 million.
Market Cap: $897.84M
VTEX, with a market cap of approximately US$897.84 million, has transitioned to profitability over the past year, reporting a net income of US$12 million for 2024 compared to a net loss the previous year. The company is debt-free and maintains strong liquidity, with short-term assets of US$284.6 million exceeding both short-term and long-term liabilities. Despite experiencing large one-off losses impacting recent financial results, VTEX’s earnings are forecasted to grow significantly at 41.22% annually. Recent developments include share buybacks totaling US$20.23 million and revenue guidance projecting growth between 14% and 17% for 2025.
NYSE:VTEX Debt to Equity History and Analysis as at Apr 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqCM:ORGO NYSE:ALIT and NYSE:VTEX.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com